🚀 VC round data is live in beta, check it out!
Roche Valuation Multiples
Discover revenue and EBITDA valuation multiples for Roche and similar public comparables like AbbVie, AstraZeneca, Novartis, Merck and more.
Roche Overview
About Roche
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Founded
1896
HQ
Employees
112.8K
Website
Financials (LTM)
EV
$400B
Roche Financials
Roche reported last 12-month revenue of $80B and EBITDA of $31B.
In the same LTM period, Roche generated $59B in gross profit, $31B in EBITDA, and $18B in net income.
Revenue (LTM)
Roche P&L
In the most recent fiscal year, Roche reported revenue of $80B and EBITDA of $31B.
Roche expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $80B | XXX | $80B | XXX | XXX | XXX |
| Gross Profit | $59B | XXX | $59B | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | $31B | XXX | $31B | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 39% | XXX | XXX | XXX |
| EBIT Margin | 35% | XXX | 35% | XXX | XXX | XXX |
| Net Profit | $18B | XXX | $18B | XXX | XXX | XXX |
| Net Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| Net Debt | — | — | $33B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Roche Stock Performance
Roche has current market cap of $377B, and enterprise value of $400B.
Market Cap Evolution
Roche's stock price is $59.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $400B | $377B | 0.0% | XXX | XXX | XXX | $2.82 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRoche Valuation Multiples
Roche trades at 5.0x EV/Revenue multiple, and 12.7x EV/EBITDA.
EV / Revenue (LTM)
Roche Financial Valuation Multiples
As of March 26, 2026, Roche has market cap of $377B and EV of $400B.
Equity research analysts estimate Roche's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Roche has a P/E ratio of 20.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $377B | XXX | $377B | XXX | XXX | XXX |
| EV (current) | $400B | XXX | $400B | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | 5.0x | XXX | XXX | XXX |
| EV/EBITDA | 12.7x | XXX | 12.7x | XXX | XXX | XXX |
| EV/EBIT | 14.1x | XXX | 14.1x | XXX | XXX | XXX |
| EV/Gross Profit | 6.7x | XXX | 6.7x | XXX | XXX | XXX |
| P/E | 20.6x | XXX | 21.0x | XXX | XXX | XXX |
| EV/FCF | 21.5x | XXX | 21.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Roche Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Roche Margins & Growth Rates
Roche's revenue in the last 12 month grew by 0%.
Roche's revenue per employee in the last FY averaged $0.7M.
Roche's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Roche's rule of X is 40% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Roche Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 39% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 16% | XXX | — | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | 24% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 20% | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Roche Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| AbbVie | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca | XXX | XXX | XXX | XXX | XXX | XXX |
| Novartis | XXX | XXX | XXX | XXX | XXX | XXX |
| Merck | XXX | XXX | XXX | XXX | XXX | XXX |
| Amgen | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Roche M&A Activity
Roche acquired XXX companies to date.
Last acquisition by Roche was on XXXXXXXX, XXXXX. Roche acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Roche
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRoche Investment Activity
Roche invested in XXX companies to date.
Roche made its latest investment on XXXXXXXX, XXXXX. Roche invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Roche
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Roche
| When was Roche founded? | Roche was founded in 1896. |
| Where is Roche headquartered? | Roche is headquartered in Switzerland. |
| How many employees does Roche have? | As of today, Roche has over 112K employees. |
| Is Roche publicly listed? | Yes, Roche is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Roche? | Roche trades under RHHBY ticker. |
| When did Roche go public? | Roche went public in 1994. |
| Who are competitors of Roche? | Roche main competitors are AbbVie, AstraZeneca, Novartis, Merck. |
| What is the current market cap of Roche? | Roche's current market cap is $377B. |
| What is the current revenue of Roche? | Roche's last 12 months revenue is $80B. |
| What is the current revenue growth of Roche? | Roche revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Roche? | Current revenue multiple of Roche is 5.0x. |
| Is Roche profitable? | Yes, Roche is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Roche? | Roche's last 12 months EBITDA is $31B. |
| What is Roche's EBITDA margin? | Roche's last 12 months EBITDA margin is 39%. |
| What is the current EV/EBITDA multiple of Roche? | Current EBITDA multiple of Roche is 12.7x. |
| What is the current FCF of Roche? | Roche's last 12 months FCF is $19B. |
| What is Roche's FCF margin? | Roche's last 12 months FCF margin is 23%. |
| What is the current EV/FCF multiple of Roche? | Current FCF multiple of Roche is 21.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.